Peroxynitrite decomposition catalyst reduces vasopressin requirement in ovine MRSA sepsis.

Arginine vasopressin Peroxynitrite decomposition catalyst Refractory shock Septic shock Vascular hypo-responsiveness WW-85

Journal

Intensive care medicine experimental
ISSN: 2197-425X
Titre abrégé: Intensive Care Med Exp
Pays: Germany
ID NLM: 101645149

Informations de publication

Date de publication:
09 Sep 2019
Historique:
received: 05 11 2018
accepted: 18 02 2019
entrez: 13 9 2019
pubmed: 13 9 2019
medline: 13 9 2019
Statut: epublish

Résumé

Sepsis is one of the most frequent causes of death in the intensive care unit. Host vascular hypo-responsiveness to vasopressors during septic shock is one of the challenging problems. This study tested the hypothesis that adjunct therapy with peroxynitrite decomposition catalyst (WW-85) would reduce arginine vasopressin (AVP) requirements during sepsis resuscitation, using ovine sepsis model. Thirteen adult female Merino sheep, previously instrumented with multiple vascular catheters, were subjected to "two-hit" (cotton smoke inhalation and intrapulmonary instillation of live methicillin-resistant Staphylococcus aureus; 3.5 × 10 The injury induced severe hypotension refractory to aggressive fluid resuscitation. High doses of AVP were required to partially attenuate the sepsis-induced hypotension. However, the cumulative AVP requirement was significantly reduced by adjunct treatment with WW-85 at 17-24 h after the injury (p < 0.05). Total AVP dose and the highest AVP rate were significantly lower in the WW-85 + AVP group compared to the AVP group (p = 0.02 and 0.04, respectively). Treatment with WW-85 had no adverse effects. In addition, the in vitro effects of AVP on isolated artery diameter changes were abolished with peroxynitrite co-incubation. The modulation of reactive nitrogen species, such as peroxynitrite, may be considered as a novel adjunct treatment option for septic shock associated with vascular hypo-responsiveness to vasopressors.

Sections du résumé

BACKGROUND BACKGROUND
Sepsis is one of the most frequent causes of death in the intensive care unit. Host vascular hypo-responsiveness to vasopressors during septic shock is one of the challenging problems. This study tested the hypothesis that adjunct therapy with peroxynitrite decomposition catalyst (WW-85) would reduce arginine vasopressin (AVP) requirements during sepsis resuscitation, using ovine sepsis model.
METHODS METHODS
Thirteen adult female Merino sheep, previously instrumented with multiple vascular catheters, were subjected to "two-hit" (cotton smoke inhalation and intrapulmonary instillation of live methicillin-resistant Staphylococcus aureus; 3.5 × 10
RESULTS RESULTS
The injury induced severe hypotension refractory to aggressive fluid resuscitation. High doses of AVP were required to partially attenuate the sepsis-induced hypotension. However, the cumulative AVP requirement was significantly reduced by adjunct treatment with WW-85 at 17-24 h after the injury (p < 0.05). Total AVP dose and the highest AVP rate were significantly lower in the WW-85 + AVP group compared to the AVP group (p = 0.02 and 0.04, respectively). Treatment with WW-85 had no adverse effects. In addition, the in vitro effects of AVP on isolated artery diameter changes were abolished with peroxynitrite co-incubation.
CONCLUSIONS CONCLUSIONS
The modulation of reactive nitrogen species, such as peroxynitrite, may be considered as a novel adjunct treatment option for septic shock associated with vascular hypo-responsiveness to vasopressors.

Identifiants

pubmed: 31512009
doi: 10.1186/s40635-019-0227-4
pii: 10.1186/s40635-019-0227-4
pmc: PMC6738358
doi:

Types de publication

Journal Article

Langues

eng

Pagination

12

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM097480
Pays : United States
Organisme : NIGMS NIH HHS
ID : GM097480
Pays : United States
Organisme : Shriners Hospitals for Children
ID : SHC84050, SHC85100

Références

Science. 1999 Nov 19;286(5444):1583-7
pubmed: 10567269
Crit Care Clin. 2000 Apr;16(2):179-92
pubmed: 10768078
J Cereb Blood Flow Metab. 2001 Mar;21(3):253-61
pubmed: 11295880
Crit Care Med. 2001 Jul;29(7):1303-10
pubmed: 11445675
Intensive Care Med. 2002 Feb;28(2):108-21
pubmed: 11907653
Anesthesiology. 2002 Sep;97(3):671-81
pubmed: 12218535
Intensive Care Med. 2003 Mar;29(3):352-60
pubmed: 12536268
N Engl J Med. 2003 Apr 17;348(16):1546-54
pubmed: 12700374
Crit Care Med. 2003 May;31(5):1394-8
pubmed: 12771608
Crit Care Med. 2004 Jan;32(1):13-20
pubmed: 14707555
Crit Care Med. 2004 Jan;32(1):21-30
pubmed: 14707556
Lancet. 2005 Jan 1-7;365(9453):63-78
pubmed: 15639681
Crit Care Med. 2006 Apr;34(4):1126-30
pubmed: 16484914
Shock. 2006 May;25(5):522-7
pubmed: 16680018
J Appl Physiol (1985). 2007 Apr;102(4):1402-9
pubmed: 17204577
Shock. 2008 May;29(5):642-9
pubmed: 17885644
J Pharmacol Exp Ther. 2008 May;325(2):475-83
pubmed: 18272810
Front Biosci (Landmark Ed). 2009 Jan 01;14:1979-89
pubmed: 19273179
Shock. 2009 Dec;32(6):621-5
pubmed: 19295474
Shock. 2010 Sep;34 Suppl 1:4-14
pubmed: 20523270
Crit Care. 2010;14(4):R129
pubmed: 20602787
Heart Lung. 2011 May-Jun;40(3):247-52
pubmed: 20630594
Biochem Biophys Res Commun. 2010 Aug 20;399(2):286-91
pubmed: 20655878
Intensive Care Med. 2010 Dec;36(12):2019-29
pubmed: 20862451
Semin Thorac Cardiovasc Surg. 2010 Summer;22(2):140-4
pubmed: 21092891
Intensive Care Med. 2011 Sep;37(9):1432-7
pubmed: 21779849
Crit Care Med. 2012 Mar;40(3):754-61
pubmed: 21963582
Intensive Care Med. 2012 Jan;38(1):9-19
pubmed: 22127480
Chest. 2013 Mar;143(3):664-671
pubmed: 22911566
Curr Vasc Pharmacol. 2013 Mar 1;11(2):196-207
pubmed: 23506498
Crit Care Med. 2014 Jul;42(7):e525-e533
pubmed: 24674922
Anesthesiology. 2014 Nov;121(5):930-6
pubmed: 25198173
Expert Opin Ther Pat. 2015 Apr;25(4):443-66
pubmed: 25576197
Shock. 2015 Oct;44(4):305-9
pubmed: 26125087
PLoS One. 2015 Dec 07;10(12):e0144345
pubmed: 26640957
Chest. 1989 Oct;96(4):885-92
pubmed: 2676394
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
Chest. 2018 Aug;154(2):416-426
pubmed: 29329694
J Int Med Res. 2018 Apr;46(4):1303-1310
pubmed: 29332515
Crit Care. 2018 Feb 27;22(1):52
pubmed: 29486781
Shock. 2018 Oct;50(4):377-380
pubmed: 30106875
JAMA. 1996 Apr 17;275(15):1192-6
pubmed: 8609688
Br J Pharmacol. 1997 Jan;120(2):259-67
pubmed: 9117118
Clin Infect Dis. 1998 Jul;27(1):185-90
pubmed: 9675475

Auteurs

Osamu Fujiwara (O)

Department of Anesthesiology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555 1102, USA.

Satoshi Fukuda (S)

Department of Anesthesiology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555 1102, USA.

Ernesto Lopez (E)

Department of Anesthesiology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555 1102, USA.

Yaping Zeng (Y)

Department of Anesthesiology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555 1102, USA.

Yosuke Niimi (Y)

Department of Anesthesiology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555 1102, USA.

Douglas S DeWitt (DS)

Department of Anesthesiology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555 1102, USA.

David N Herndon (DN)

Shriners Hospital for Children, Galveston, Texas, USA.
Department of Surgery, University of Texas Medical Branch, Galveston, Texas, USA.

Donald S Prough (DS)

Department of Anesthesiology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555 1102, USA.

Perenlei Enkhbaatar (P)

Department of Anesthesiology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX, 77555 1102, USA. peenkhba@utmb.edu.
Shriners Hospital for Children, Galveston, Texas, USA. peenkhba@utmb.edu.

Classifications MeSH